Clinical Trials Browser

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Pleural Effusion, Malignant

NCT01556191 2021-01-08

LADIE

Phase 2 Completed

379 enrolled

Thoracic

Lung Neoplasms

NCT00888511 2020-11-27

TARLAL

Phase 2 Completed

15 enrolled 6 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04575415 2020-10-20

BELLA

Unknown

272 enrolled

Thoracic

NSCLC

NCT01188707 2020-10-19

A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer

Phase 1/2 Terminated

5 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00835471 2020-09-29

NVALT10

Phase 2 Completed

195 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00950365 2020-09-16

Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer

Phase 2 Completed

79 enrolled 13 charts

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung

NCT00547105 2020-08-21

Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 2 Completed

24 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00278148 2020-07-20

Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer

Phase 1/2 Completed

32 enrolled 13 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01857271 2020-07-08

EVENT

Phase 2 Terminated

3 enrolled 5 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04455594 2020-07-02

ANSWER

Phase 2 Unknown

168 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Unknown

4,724 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00966472 2020-04-21

Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC

Phase 1 Completed

24 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell

NCT00137800 2020-04-03

Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients

Phase 2 Completed

82 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00411632 2020-01-29

BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

37 enrolled 9 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00200395 2019-12-30

OSI-774 (Erlotinib, Tarceva) in Elderly Patients

Phase 2 Completed

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00137839 2019-12-17

Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung

Phase 2 Completed

84 enrolled 12 charts

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT02770014 2019-11-22

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Phase 2 Terminated

43 enrolled 8 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00563784 2019-11-20

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

68 enrolled 11 charts

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Adenocarcinoma, Clear Cell, Carcinoma, Giant Cell

NCT00581789 2019-11-19

Erlotinib and Sunitinib in NSCLC

Phase 1 Completed

11 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04145570 2019-10-30

A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions

Phase 4 Completed

24 enrolled

Thoracic

Lung Neoplasms

NCT01259089 2019-09-11

Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

Phase 1/2 Completed

38 enrolled 12 charts

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT00153803 2019-09-06

Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Completed

245 enrolled 13 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04007835 2019-07-05

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Phase NA Unknown

120 enrolled

Thoracic

NSCLC

NCT00300586 2019-05-28

IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer

Phase 3 Completed

842 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT00354549 2019-05-15

Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC

Phase 2 Completed

104 enrolled

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01116219 2019-05-15

Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).

Phase 2 Completed

149 enrolled

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02080078 2019-05-03

A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline

Phase 1 Terminated

15 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Diarrhea

Clinical Trials

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer

Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.

EURTAC

Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

PIKACHU

Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer

BLISS

ROME

BEVERLY

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

NSCLC

SLAT

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer

Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer

Sindas

Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

LADIE

TARLAL

BELLA

A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer

NVALT10

Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer

Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer

EVENT

ANSWER

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC

Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients

BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

OSI-774 (Erlotinib, Tarceva) in Elderly Patients

Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

Erlotinib and Sunitinib in NSCLC

A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions

Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer

Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC

Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).

A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline